AI assistant
Axogen, Inc. — Director's Dealing 2021
Mar 18, 2021
32414_dirs_2021-03-18_492bf9e9-f92b-49bc-8a6e-87d85d424f3e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Axogen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2021-03-16
Reporting Person: Billet Isabelle (Chief Strategy and BD Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-16 | Employee Stock Option (right to purchase) | $20.91 | A | 23500 | Acquired | 2031-03-16 | Common Stock (23500.0) | Direct |
| 2021-03-16 | Restricted Stock Units | $ | A | 11800 | Acquired | Common Stock (11800.0) | Direct |
Footnotes
F1: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F3: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.